Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 902 results for "astrazeneca"

EMA recommends marketing approval for AstraZeneca's Zavicefta ...

The European Medicines Agency (EMA) has recommended granting a marketing authorisation in the European Union (EU) for AstraZeneca's Zavicefta (ceftazidime/avibactam), a new treatment option against multi-drug resistant bacteria. The lack of ... PharmaBiz, 23 hours ago
American Banking News - Earnings

AstraZeneca plc (AZN) Stock Rating Reaffirmed by Jefferies Group

AstraZeneca plc (LON:AZN)s stock had its hold rating reissued by equities research analysts at Jefferies Group in a report released on Friday, AnalystRatings.Net reports. They currently have a GBX 4,200 ($59.97) price objective on the ...
 American Banking News - Earnings8 hours ago AstraZeneca plc's (AZN) Equal Weight Rating Reaffirmed at Barclays  Mideast Time1 day ago Analysts Weekly Ratings Updates for AstraZeneca plc (AZN)  American Banking News - Forex2 days ago BNP Paribas Reaffirms Outperform Rating for AstraZeneca plc (AZN)  WKRB News2 days ago
Bidness Etc

AstraZeneca Gains on New Cost-Cutting Plans

AstraZeneca Plc ADR ( NYSE:AZN ) announced financial results for the first quarter (1Q) of fiscal 2016 with a fall in earnings. The drug maker's top-selling products continued to decline on increasing generic competition, while research spending ...
 Bidness Etc1 day ago AstraZeneca 1Q Core Earnings Per Share Misses Estimate  Bloomberg1 day ago AstraZeneca Earnings Fall as Recent Acquisitions Push Up Costs  La Repubblica1 day ago AstraZeneca Profit Falls as Recent Purchases Push Up Costs  Bloomberg1 day ago

FDA approves first generic version of AstraZeneca's top drug Crestor

The FDA approves a generic version of AstraZeneca's ( AZN -0.6%) cholesterol fighter Crestor (rosuvastatin calcium), from Watson Pharmaceuticals (now part of Teva Pharmaceutical Industries ( TEVA -0.7%)). The branded version is AstraZeneca's top ...
 Seeking Alpha1 day ago FDA Gives Approval to First Generic Crestor Cholesterol Drug  InvestorPlace.com1 day ago AstraZeneca tightens focus as Crestor generics loom  MedNous1 day ago AZ looks to cancer drugs as Crestor nears generic cliff  pharmaphorum1 day ago

AstraZeneca's (AZN) CEO Pascal Soriot on Q1 2016 Results - Earnings Call Transcript

AstraZeneca Plc (NYSE: AZN ) Q1 2016 Earnings Conference Call April 28, 2016 7:00 AM ET Executives Pascal Soriot - Chief Executive Officer & Executive Director Luke Miels - Executive Vice President Global Product and Portfolio ...
 Seeking Alpha1 day ago Result of AGM  MoneyAM1 day ago AstraZeneca PLC AZN: 1st Quarter Results  ADVFN UK1 day ago AstraZeneca share price: Externalisation drives Q1 revenue higher  Invezz1 day ago
Investor's Business Daily

AstraZeneca, Pfizer Said Among Firms Weighing Medivation Bid

Rival drug companies considering challenge to Sanofi's offer Medivation rejected Sanofi's $52.50 a share bid on Friday AstraZeneca Plc and Pfizer Inc. are among firms considering a counteroffer for Medivation Inc., challenging Sanofi's $9.3 ...
 Bloomberg1 day ago Medivation Rejects Sanofi's Buyout Bid; Sanofi Remains Committed  Investor's Business Daily1 day ago Sanofi makes a bid for Medivation  Chemical & Engineering News2 days ago

AstraZeneca Q1 top line up 1%; EPS down 16%; CF Ops ~1.2B

AstraZeneca (NYSE: AZN ) Q1 results ($M): Total Revenues: 6,115 (+1.0%); Total Product Sales: 5,565 (-3.2%); U.S.; 2,246 (+3.6%); Europe: 1,218 (-9.1%); Established ROW: 636 (-9.9%); Japan: 429 (-5.7%); Emerging Markets: 1,465 (-4.4%); China: 774 ...
 Seeking Alpha1 day ago

AstraZeneca's Lynparza available for BRCAm ovarian cancer patients in NHS England and Wales

Biopharmaceutical company AstraZeneca has revealed that Lynparza (olaparib) is currently available for National Health Service (NHS) patients in England and Wales suffering from platinum-sensitive relapsed (PSR), BRCA-mutated (BRCAm), high-grade ...
 Pharmaceutical Technology1 day ago

Do today's results make AstraZeneca plc & Laird PLC the ultimate dividend buys?

Pharmaceutical heavyweight AstraZeneca (LSE: AZN) said this morning that profits from the firm's core business fell by 12% during the first quarter, due to acquisitions and increased investment in new cancer treatments. Core earnings dropped by ...
 Yahoo! Finance UK and Ireland1 day ago

AstraZeneca misses by $0.01, beats on revenue

s Editor AstraZeneca (NYSE:AZN): Q1 EPS of $0.95 misses by $0.01. Revenue of $6.12B (+1.0% Y/Y) beats
 Seeking Alpha1 day ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - astrazeneca
Get updated on latest news & your favorite topics right in your inbox!
More     Less